• news.cision.com/
  • DBP/
  • Temodex/SI053 will be presented at international conferences in North and South America

Temodex/SI053 will be presented at international conferences in North and South America

Report this content

Temodex and Double Bond Pharmaceutical’s drug candidate SI053 will be presented at "Joint Conference of the Society for Neuro-Oncology and the Society for CNS Interstitial Delivery of Therapeutics on Therapeutic Delivery to the CNS" at November 20-21th (Phoenix, Arizona) and at "VII Congreso Massin, Society of International Neurosurgeons ”November 21-23 (Cartagene, Colombia).

"I am pleased that we will present the experience with the use of Temodex and our development plans regarding SI053 to world experts in neuro-oncology on both American continents", - comments CEO Igor Lokot

More about Temodex: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o

More about Joint Conference of The Society for Neuro-Oncology and the Society for CNS Interstitial Delivery of Therapeutics on Therapeutic Delivery to the CNS: https://www.soc-neuro-onc.org/SNO/SCIDOT-SNO_2019.aspx  

____________________________________________________________________ 

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:         SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

Subscribe

Documents & Links